It’s been a while since we did a financing roundup – let’s get to it…

• Last week, Lumavita AG raised CHF 6M ($5.53M) in a new Series A round bringing the total raised to CHF 24M ($22M). HealthCap led the tranche and was joined by return backer Endeavour Vision. The funds will be used to build Lumavita’s “commercial partnering network” for FemiFect® (pentamycin), for the treatment of vaginitis, and to finance two on-going development projects. [peHUB]

• Zymeworks Inc. says it has raised $3.5M with participation by CTI Life Sciences Fund. Zymeworks will use the funds for ongoing validation and research programs for its protein therapeutics pipeline. [BusinessWire]

• Intrexon Corporation has closed an additional $10M of a Series C-2 financing from New River Management V, LP, a life sciences-focused investment fund managed by Third Security, LLC. Intrexon will put the funds toward its modular inducible cancer immunotherapeutic (MICI) platform, as well as its recently initiated Phase 1b study in patients with melanoma. [MarketWatch]

• EyeIC has raised $1.9M for its glaucoma-screening software. EyeIC’s software, called MatchedFlicker, aids in glaucoma diagnosis by allowing physicians to monitor retinal photographs over time to mark changes and detect progressions of disease. The company plans to start commercializing the software in July, and will be sold either as a subscription or licensed to ophthalmologists and optometrists following a free trial. [Reuters]

• CNS Response, Inc. has received a $1M bridge loan from venture capitalist John Pappajohn. The funds will be used to finish the company’s Referenced-EEG® clinical trial for treatment-resistant depression. [SYS-CON]

• Cytox Limited has closed a pre-Series A funding round of GBP 600,000 ($1M USD). The $1M will be used to advance commercialization of the company’s testing services for Alzheimer’s disease and mild cognitive impairment. Midven Limited was the lead investor. [PRNewswire]

• GenScript Inc. closed a $15M venture funding to expand its biology services in drug discovery and development. The investment was led by Kleiner Perkins Caufield & Byers (KPCB) China Fund and a co-investor, TBIG Healthcare. [PRLog]

Public Financings & Offerings

• Halozyme Therapeutics Inc. (HALO) raised $40M through a sale of 6.15M shares of its common stock at $6.50 per share, which was more than a 13 percent discount from Monday’s market closing of $7.53. The funds will be used for the company’s insulin, oncology and dermatology programs as well as other general corporate purposes. HALO’s lead program is PH20, a recombinant human hyaluronidase enzyme in Phase 2 trials for diabetes. [BioWorld Online]

• Finally, ImmunoGen Inc. completed its previously announced sale of more than 5M shares of common stock bringing in proceeds of $38M. The company plans to use the funds for general corporate purposes, including research and development. [AP]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts